<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088279</url>
  </required_header>
  <id_info>
    <org_study_id>246688</org_study_id>
    <nct_id>NCT04088279</nct_id>
  </id_info>
  <brief_title>Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)</brief_title>
  <official_title>Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study of the use of two novel MRI techniques (oxygen-enhanced and fourier
      decomposition MRI) in the initial diagnosis and follow-up of patients with Pulmonary
      Hypertension. The investigators believe these techniques may present a novel set of imaging
      biomarkers that may be used for risk stratification, prediction of treatment response and
      longitudinal disease monitoring. The reserach MRI is in addition to standard of care and will
      not affect treatment decisions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta pO2 max (mmHg)</measure>
    <time_frame>Baseline and 3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wash in and wash out time constants (min)</measure>
    <time_frame>Baseline and 3-6months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Signal Intensity Change (%)</measure>
    <time_frame>Baseline and 3-6months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractions (% area of lung imaged)</measure>
    <time_frame>Baseline and 3-6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Oxygen enhanced and fourier decomposition MRI</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Pulmonary Hypertension.

          -  Age 18 and over.

        Exclusion Criteria:

          -  Standard contra-indications to MRI (as per NHS MRI safety questionnaire).

          -  Not medically fit for transfer to MRI.

          -  Patient judged inappropriate for involvement in study by clinical team e.g. secondary
             to emotional burden of recent diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Padley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrik Pettersson</last_name>
    <phone>0330 128 8736</phone>
    <email>p.pettersson@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobi Sathianandan, MBBS</last_name>
      <email>s.sathianandan@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>oxygen enhanced</keyword>
  <keyword>fourier decomposition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

